{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:55:55Z","timestamp":1787162155459,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Genentech Inc, South San Francisco, CA, USA."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s12325-024-02850-9","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T02:02:28Z","timestamp":1714960948000},"page":"2446-2459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adherence and Persistence Among Risdiplam-Treated Individuals with Spinal Muscular Atrophy: A Retrospective Claims Analysis"],"prefix":"10.1007","volume":"41","author":[{"given":"Elmor D.","family":"Pineda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu My","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis L.","family":"Dickendesher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Shapouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan T.","family":"Iannaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"issue":"3","key":"2850_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","volume":"62","author":"BT Darras","year":"2015","unstructured":"Darras BT. Spinal muscular atrophies. Pediatr Clin North Am. 2015;62(3):743\u201366.","journal-title":"Pediatr Clin North Am"},{"issue":"4","key":"2850_CR2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831\u201346.","journal-title":"Neurol Clin"},{"issue":"1","key":"2850_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365.","journal-title":"Cell"},{"key":"2850_CR4","volume-title":"GeneReviews\u00ae","author":"TW Prior","year":"1993","unstructured":"Prior TW, Leach ME, Finanger E. Spinal muscular atrophy. In: Adam MP, et al., editors. GeneReviews\u00ae. Seattle, WA: University of Washington; 1993."},{"key":"2850_CR5","unstructured":"Biogen Inc. SPINRAZA\u00ae (nusinersen) US prescribing information. December 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/209531lbl.pdf. Accessed Apr 2024."},{"key":"2850_CR6","unstructured":"Novartis Gene Therapies, Inc. ZOLGENSMA\u00ae (onasemnogene abeparvovec-xioi) US prescribing information. December 2023. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/zolgensma.pdf. Accessed Apr 2024."},{"key":"2850_CR7","unstructured":"US Food and Drug Administration. EVRYSDI\u2122 highlights of prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213535s000lbl.pdf. Accessed Apr 2024."},{"key":"2850_CR8","unstructured":"Cure SMA. FDA approves Genentech\u2019s Evrysdi (risdiplam) for use in babies under two months with spinal muscular atrophy. 2022. https:\/\/www.curesma.org\/fda-approves-genentechs-evrysdi-risdiplam-for-use-in-babies-under-two-months-with-spinal-muscular-atrophy\/. Accessed Apr 2024."},{"issue":"1","key":"2850_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","volume":"7","author":"DC Schorling","year":"2020","unstructured":"Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy\u2014new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(1):1\u201313.","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"2850_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103\u201315.","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"2850_CR11","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/s41591-022-01889-x","volume":"28","author":"CJ Sumner","year":"2022","unstructured":"Sumner CJ, Crawford TO. Early treatment is a lifeline for infants with SMA. Nat Med. 2022;28(7):1348\u20139.","journal-title":"Nat Med"},{"issue":"12","key":"2850_CR12","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","volume":"21","author":"R Masson","year":"2022","unstructured":"Masson R, Mazurkiewicz-Beldzinska M, Rose K, et al. Safety and efficacy of risdiplam in patients with type\u00a01 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet Neurol. 2022;21(12):1110\u20139.","journal-title":"Lancet Neurol"},{"issue":"18","key":"2850_CR13","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"2850_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase\u00a03 trial. Lancet Neurol. 2021;20(4):284\u201393.","journal-title":"Lancet Neurol"},{"issue":"1","key":"2850_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13023-023-02769-4","volume":"18","author":"A \u0141usakowska","year":"2023","unstructured":"\u0141usakowska A, W\u00f3jcik A, Fr\u0105czek A, et al. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience. Orphanet J Rare Dis. 2023;18(1):230.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2850_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mus.27804","volume":"67","author":"NC \u00d1ungo Garz\u00f3n","year":"2023","unstructured":"\u00d1ungo Garz\u00f3n NC, Pitarch Castellano I, Sevilla T, V\u00e1zquez-Costa JF. Risdiplam in non-sitter patients aged 16\u00a0years and older with 5q spinal muscular atrophy. Muscle Nerve. 2023;67(5):407\u201311.","journal-title":"Muscle Nerve"},{"key":"2850_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JND-230197","volume":"11","author":"B Sitas","year":"2023","unstructured":"Sitas B, Hancevic M, Bilic K, Bilic H, Bilic E.\u00a0Risdiplam real world data\u2014looking beyond motor neurons and motor function measures. J Neuromuscular Dis. 2023;11:75\u201384.","journal-title":"J Neuromuscular Dis"},{"issue":"2","key":"2850_CR18","doi-asserted-by":"publisher","first-page":"25579","DOI":"10.52965\/001c.25579","volume":"13","author":"J Kakazu","year":"2021","unstructured":"Kakazu J, Walker NL, Babin KC, et al. Risdiplam for the use of spinal muscular atrophy. Orthop Rev (Pavia). 2021;13(2):25579.","journal-title":"Orthop Rev (Pavia)"},{"issue":"7","key":"2850_CR19","first-page":"604","volume":"8","author":"MS Weaver","year":"2021","unstructured":"Weaver MS, Yuroff A, Sund S, Hetzel S, Halanski MA. Quality of life outcomes according to differential nusinersen exposure in pediatric spinal muscular atrophy. Children (Basel). 2021;8(7):604.","journal-title":"Children (Basel)"},{"issue":"12","key":"2850_CR20","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1007\/s12325-021-01938-w","volume":"38","author":"M Gauthier-Loiselle","year":"2021","unstructured":"Gauthier-Loiselle M, Cloutier M, Toro W, et al. Nusinersen for spinal muscular atrophy in the United States: findings from a retrospective claims database analysis. Adv Ther. 2021;38(12):5809\u201328.","journal-title":"Adv Ther"},{"issue":"3","key":"2850_CR21","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s12325-022-02376-y","volume":"40","author":"D Fox","year":"2022","unstructured":"Fox D, To TM, Seetasith A, Patel AM, Iannaccone ST. Adherence and persistence to nusinersen for spinal muscular atrophy: a US claims-based analysis. Adv Ther. 2022;40(3):903\u201319.","journal-title":"Adv Ther"},{"issue":"3","key":"2850_CR22","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s12325-022-02414-9","volume":"40","author":"B Youn","year":"2023","unstructured":"Youn B, Proud CM, Wang N, et al. Examining real-world adherence to nusinersen for the treatment of spinal muscular atrophy using two large US data sources. Adv Ther. 2023;40(3):1129\u201340.","journal-title":"Adv Ther"},{"issue":"1","key":"2850_CR23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/13696998.2019.1646263","volume":"23","author":"M Droege","year":"2020","unstructured":"Droege M, Sproule D, Arjunji R, Gauthier-Loiselle M, Cloutier M, Dabbous O. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment. J Med Econ. 2020;23(1):70\u20139.","journal-title":"J Med Econ"},{"key":"2850_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-020-01667-3","volume":"16","author":"A Monette","year":"2021","unstructured":"Monette A, Chen E, Bazzano A, Dixon S, David Arnold W, Shi L. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis. 2021;16:36.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"2850_CR25","first-page":"1073","volume":"25","author":"SL Canfield","year":"2019","unstructured":"Canfield SL, Zuckerman A, Anguiano RH, et al. Navigating the Wild West of medication adherence reporting in specialty pharmacy. J Manage Care Spec Pharm. 2019;25(10):1073\u20137.","journal-title":"J Manage Care Spec Pharm"},{"issue":"5","key":"2850_CR26","first-page":"639","volume":"27","author":"NJ Engmann","year":"2021","unstructured":"Engmann NJ, Sheinson D, Bawa K, Ng CD, Pardo G. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. J Manage Care Spec Pharm. 2021;27(5):639\u201349.","journal-title":"J Manage Care Spec Pharm"},{"issue":"1","key":"2850_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40120-021-00319-3","volume":"11","author":"G Pardo","year":"2022","unstructured":"Pardo G, Pineda ED, Ng CD, Bawa KK, Sheinson D, Bonine NG. Adherence to and persistence with disease-modifying therapies for multiple sclerosis over 24\u00a0months: a retrospective claims analysis. Neurol Ther. 2022;11(1):337\u201351.","journal-title":"Neurol Ther"},{"key":"2850_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2147\/PPA.S40736","volume":"7","author":"CM Kozma","year":"2013","unstructured":"Kozma CM, Dickson M, Phillips AL, Meletiche DM. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adher. 2013;7:509\u201316.","journal-title":"Patient Prefer Adher"},{"issue":"2","key":"2850_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/mus.28015","volume":"69","author":"JC Powell","year":"2023","unstructured":"Powell JC, Meiling JB, Cartwright MS. A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy. Muscle Nerve. 2023;69(2):179\u201384.","journal-title":"Muscle Nerve"},{"issue":"11","key":"2850_CR30","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1136\/archdischild-2023-325762","volume":"108","author":"L Xiao","year":"2023","unstructured":"Xiao L, Kang S, Djordjevic D, et al.\u00a0Understanding caregiver experiences with disease-modifying therapies for spinal muscular atrophy: a qualitative study. Arch Dis Child. 2023;108(11):929\u201334.","journal-title":"Arch Dis Child"},{"issue":"5","key":"2850_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.nmd.2021.01.012","volume":"31","author":"N Gusset","year":"2021","unstructured":"Gusset N, Stalens C, Stumpe E, et al. Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy. Neuromuscul Disord. 2021;31(5):419\u201330.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"2850_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13023-019-1052-2","volume":"14","author":"HWY Wan","year":"2019","unstructured":"Wan HWY, Carey KA, D'Silva A, Kasparian NA, Farrar MA. \u201cGetting ready for the adult world\u201d: how adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being. Orphanet J Rare Dis. 2019;14(1):74.","journal-title":"Orphanet J Rare Dis"},{"issue":"20","key":"2850_CR33","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1212\/WNL.0000000000006502","volume":"91","author":"D Michelson","year":"2018","unstructured":"Michelson D, Ciafaloni E, Ashwal S, et al. Evidence in focus: Nusinersen use in spinal muscular atrophy: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;91(20):923\u201333.","journal-title":"Neurology"},{"issue":"5","key":"2850_CR34","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1212\/CPJ.0000000000000718","volume":"9","author":"CD Zingariello","year":"2019","unstructured":"Zingariello CD, Brandsema J, Drum E, et al. A multidisciplinary approach to dosing nusinersen for spinal muscular atrophy. Neurol Clin Pract. 2019;9(5):424\u201332.","journal-title":"Neurol Clin Pract"},{"issue":"3","key":"2850_CR35","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/mus.27116","volume":"63","author":"E Chen","year":"2021","unstructured":"Chen E, Dixon S, Naik R, et al. Early experiences of nusinersen for the treatment of spinal muscular atrophy: results from a large survey of patients and caregivers. Muscle Nerve. 2021;63(3):311\u20139.","journal-title":"Muscle Nerve"},{"key":"2850_CR36","doi-asserted-by":"publisher","first-page":"175628641988761","DOI":"10.1177\/1756286419887616","volume":"13","author":"I Cordts","year":"2020","unstructured":"Cordts I, Lingor P, Friedrich B, et al. Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy. Ther Adv Neurol Disord. 2020;13:1756286419887616.","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"2850_CR37","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691\u2013705.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2850_CR38","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3233\/JND-210768","volume":"9","author":"L Elman","year":"2022","unstructured":"Elman L, Youn B, Proud CM, et al. Real-world adherence to nusinersen in adults with spinal muscular atrophy in the US: a multi-site chart review study. J Neuromuscul Dis. 2022;9(5):655\u201360.","journal-title":"J Neuromuscul Dis"},{"key":"2850_CR39","doi-asserted-by":"crossref","unstructured":"Lam, WY, Fresco, P. Medication Adherence Measures: An Overview. Biomed Res Int, 2015. 2015: p. 217047","DOI":"10.1155\/2015\/217047"},{"issue":"5","key":"2850_CR40","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s11606-020-06447-0","volume":"36","author":"ME Wilder","year":"2021","unstructured":"Wilder ME, Kulie P, Jensen C, et al. The impact of social determinants of health on medication adherence: a systematic review and meta-analysis. J Gen Intern Med. 2021;36(5):1359\u201370.","journal-title":"J Gen Intern Med"},{"issue":"5","key":"2850_CR41","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487\u201397.","journal-title":"N Engl J Med"},{"issue":"1","key":"2850_CR42","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1353\/hpu.2017.0036","volume":"28","author":"CY Osborn","year":"2017","unstructured":"Osborn CY, Kripalani S, Goggins KM, Wallston KA. Financial strain is associated with medication nonadherence and worse self-rated health among cardiovascular patients. J Health Care Poor Underserved. 2017;28(1):499\u2013513.","journal-title":"J Health Care Poor Underserved"},{"issue":"6","key":"2850_CR43","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/MLR.0b013e318032937e","volume":"45","author":"MR DiMatteo","year":"2007","unstructured":"DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care. 2007;45(6):521\u20138.","journal-title":"Med Care"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02850-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02850-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02850-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T09:25:32Z","timestamp":1716888332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02850-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2850"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02850-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"24 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Elmor D. Pineda, Tu My To, Travis Dickendesher, and Sheila Shapouri are employees of Genentech Inc and shareholders of F. Hoffmann-La Roche Ltd. Susan T. Iannaccone has received funding from the National Institutes of Health, Muscular Dystrophy Association, Parent Project Muscular Dystrophy, Cure SMA, Department of Defense, AveXis, Biogen, PTC Therapeutics, Sarepta, FibroGen, Pfizer and ScholarRock.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"The present study made use of deidentified data and was thus exempt from the institutional review board review. This research was compliant with the Health Insurance Portability and Accountability Act. Genentech, Inc, has a data use agreement with the specialty pharmacy utilized in this study, which allows Genentech-associated researchers to use and analyze their data and to publish the corresponding results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}